Famygen Life Sci Drug Patent Portfolio
Famygen Life Sci owns 1 orange book drug protected by 6 US patents Given below is the list of Famygen Life Sci's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11400077 | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | 25 Oct, 2039 | Active |
| US10278918 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | 31 Jan, 2034 | Active |
| US10772829 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | 31 Jan, 2034 | Active |
| US11090261 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | 31 Jan, 2034 | Active |
| US11844858 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | 31 Jan, 2034 | Active |
| US9795560 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof | 31 Jan, 2034 | Active |
Latest Legal Activities on Famygen Life Sci's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Famygen Life Sci.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Mar, 2024 | US10772829 |
|
Electronic Review
Critical
| 02 Feb, 2024 | US11844858 |
|
Email Notification
Critical
| 20 Dec, 2023 | US11844858 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 19 Dec, 2023 | US11844858 |
|
Recordation of Patent Grant Mailed
Critical
| 19 Dec, 2023 | US11844858 |
| Recordation of Patent eGrant | 19 Dec, 2023 | US11844858 |
| Patent eGrant Notification | 19 Dec, 2023 | US11844858 |
| Mail Patent eGrant Notification | 19 Dec, 2023 | US11844858 |
|
Email Notification
Critical
| 30 Nov, 2023 | US11844858 |
|
Issue Notification Mailed
Critical
| 29 Nov, 2023 | US11844858 |
| Dispatch to FDC | 15 Nov, 2023 | US11844858 |
|
Application Is Considered Ready for Issue
Critical
| 15 Nov, 2023 | US11844858 |
|
Issue Fee Payment Verified
Critical
| 08 Nov, 2023 | US11844858 |
|
Issue Fee Payment Received
Critical
| 08 Nov, 2023 | US11844858 |
|
Email Notification
Critical
| 09 Aug, 2023 | US11844858 |
Famygen Life Sci's Family Patents
Famygen Life Sci Drug List
Given below is the complete list of Famygen Life Sci's drugs and the patents protecting them.
1. Ryzumvi
Ryzumvi is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11400077 | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders |
25 Oct, 2039
(14 years from now)
| Active |
| US10278918 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
31 Jan, 2034
(9 years from now)
| Active |
| US10772829 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
31 Jan, 2034
(9 years from now)
| Active |
| US11090261 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
31 Jan, 2034
(9 years from now)
| Active |
| US11844858 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
31 Jan, 2034
(9 years from now)
| Active |
| US9795560 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
31 Jan, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ryzumvi's drug page